ATE246676T1 - Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren - Google Patents

Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren

Info

Publication number
ATE246676T1
ATE246676T1 AT99970084T AT99970084T ATE246676T1 AT E246676 T1 ATE246676 T1 AT E246676T1 AT 99970084 T AT99970084 T AT 99970084T AT 99970084 T AT99970084 T AT 99970084T AT E246676 T1 ATE246676 T1 AT E246676T1
Authority
AT
Austria
Prior art keywords
carbons
retinoid
receptors
alkyl
selective activity
Prior art date
Application number
AT99970084T
Other languages
English (en)
Inventor
Jayasree Vasudevan
Vidyasagar Vuligonda
Richard L Beard
Roshantha A Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE246676T1 publication Critical patent/ATE246676T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99970084T 1998-10-01 1999-09-21 Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren ATE246676T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,949 US6048873A (en) 1998-10-01 1998-10-01 Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
PCT/US1999/021857 WO2000020397A1 (en) 1998-10-01 1999-09-21 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors

Publications (1)

Publication Number Publication Date
ATE246676T1 true ATE246676T1 (de) 2003-08-15

Family

ID=22596785

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99970084T ATE246676T1 (de) 1998-10-01 1999-09-21 Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren
AT03016595T ATE310727T1 (de) 1998-10-01 1999-09-21 Tetrahydrochinolinderivate mit selektiver aktivität für retinoid x rezeptoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03016595T ATE310727T1 (de) 1998-10-01 1999-09-21 Tetrahydrochinolinderivate mit selektiver aktivität für retinoid x rezeptoren

Country Status (11)

Country Link
US (1) US6048873A (de)
EP (2) EP1354878B1 (de)
JP (1) JP2002526534A (de)
AT (2) ATE246676T1 (de)
AU (1) AU763108B2 (de)
CA (1) CA2346037A1 (de)
DE (2) DE69910231T2 (de)
DK (1) DK1117648T3 (de)
ES (1) ES2201835T3 (de)
HK (2) HK1039121A1 (de)
WO (1) WO2000020397A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2335335A (en) * 1998-03-13 1999-09-15 Northern Telecom Ltd Carrying speech-band signals over power lines
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6291677B1 (en) 2000-08-29 2001-09-18 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6388105B1 (en) * 2001-09-27 2002-05-14 Allergan Sales, Inc. Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6720423B2 (en) 2002-04-30 2004-04-13 Allergan, Inc. Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
CA2500582A1 (en) * 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US6683092B1 (en) 2003-04-09 2004-01-27 Allergan, Inc. [3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6936636B2 (en) * 2003-06-26 2005-08-30 Allergan, Inc. 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en) 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
BRPI0608553A2 (pt) * 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
EP1937641A2 (de) * 2005-09-30 2008-07-02 Janssen Pharmaceutica, N.V. Dihydro-[1h]-chinolin-2-onderivate als rxr-agonisten zur behandlung von dyslipidämie, hypercholesterinämie und diabetes
AU2006299645B2 (en) 2005-09-30 2011-02-03 Io Therapeutics, Llc Treatment of cancer with specific RXR agonists
CA2624345A1 (en) * 2005-09-30 2007-04-12 Janssen Pharmaceutica N.V. 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
JP2009513570A (ja) * 2005-09-30 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 異常脂血症、高コレステロール血症及び糖尿病の処置のためのrxrアゴニストとしての複素環式アミド誘導体
US20070185055A1 (en) * 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
US20090197878A1 (en) * 2008-02-01 2009-08-06 Wyeth SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR
EP2790698A1 (de) 2011-12-13 2014-10-22 IO Therapeutics, Inc. Behandlung von autoimmunerkrankungen mit rxr-agonisten
US9422281B2 (en) 2013-11-18 2016-08-23 Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
US9877941B2 (en) 2015-10-31 2018-01-30 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
MX2018010863A (es) 2016-03-10 2019-01-10 Io Therapeutics Inc Tratamiento contra trastornos musculares con combinaciones de agonistas rxr y hormonas tiroideas.
NZ745703A (en) 2016-03-10 2019-10-25 Io Therapeutics Inc Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
MY196734A (en) 2017-11-17 2023-05-03 Io Therapeutics Inc Compounds and synthetic methods for the preparation of retinoid x receptor-specific retinoids
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
WO2023108012A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist and taxanes in treating her2+ cancers
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264578A (en) * 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
DK0617614T3 (da) * 1991-12-18 1998-09-28 Salk Inst For Biological Studi Midler til modulering af processer medieret af retinoide receptorer og forbindelser anvendlige dertil
DE69329278T2 (de) * 1992-04-22 2001-08-09 Ligand Pharmaceuticals, Inc. Retinoid-x rezeptor selektive verbindungen
CA2153236A1 (en) * 1993-01-11 1995-02-09 Marcus F. Boehm Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
PL180048B1 (en) * 1994-08-10 2000-12-29 Fhoffmann La Roche Ag Ligands of retinic acid x-receptors
JP3826182B2 (ja) * 1994-10-31 2006-09-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 モノ又はポリエンカルボン酸誘導体
US5616712A (en) * 1995-05-16 1997-04-01 Allergan Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
JP2002515025A (ja) * 1995-10-06 2002-05-21 リガンド・ファーマシューティカルズ・インコーポレイテッド ダイマー選択的rxrモジュレーターおよびその使用方法
AU7598596A (en) * 1995-11-01 1997-05-22 Allergan, Inc. Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity

Also Published As

Publication number Publication date
ES2201835T3 (es) 2004-03-16
JP2002526534A (ja) 2002-08-20
EP1117648A1 (de) 2001-07-25
EP1354878A3 (de) 2003-12-10
HK1039121A1 (en) 2002-04-12
EP1354878A2 (de) 2003-10-22
DK1117648T3 (da) 2003-11-17
CA2346037A1 (en) 2000-04-13
WO2000020397A1 (en) 2000-04-13
DE69910231T2 (de) 2004-06-09
DE69928583T2 (de) 2006-08-10
EP1117648B1 (de) 2003-08-06
DE69910231D1 (de) 2003-09-11
AU763108B2 (en) 2003-07-10
AU6054799A (en) 2000-04-26
ATE310727T1 (de) 2005-12-15
DE69928583D1 (de) 2005-12-29
EP1354878B1 (de) 2005-11-23
HK1057213A1 (en) 2004-03-19
US6048873A (en) 2000-04-11

Similar Documents

Publication Publication Date Title
ATE246676T1 (de) Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren
DE3688374D1 (de) Pyrazolsulfonamidderivat, verfahren zu seiner herstellung und dieses enthaltendes herbizid.
KR950005827A (ko) 신규 2- 아미노티아졸카르복사미드 유도체, 그의 제조방법 및 식물병원균 퇴치를 위한 그의 용도
FI982436A0 (fi) Kondensoituneet heterosykliset yhdisteet
DE69331414D1 (de) Depsipeptide, herstellung und anwendung
BR8704582A (pt) Processo para preparar derivados de piridinacarboxamida
NO981269D0 (no) Forbindelser som forsterker virkningen av retinoider
KR870000288A (ko) (메트)-아크릴산 에스테르의 제조방법
KR960703902A (ko) 피라졸유도체
FI914187A (fi) Menetelmä valmistaa kaavan /I/ mukaista 1-metyylikarbapeneemijohdosta
DE69921151D1 (de) Fluorszierende marker
ATE73451T1 (de) Verfahren zur herstellung von 3imidazolylmethyltetrahydrocarbazolonen.
DK0719277T3 (da) Androstenoner
ATE73452T1 (de) Verfahren zur herstellung von 3imidazolylmethyltetrahydrocarbazolonen.
TW427979B (en) A condensed piperidine compound
KR920004353A (ko) 4,5,6,7-테트라하이드로-3-아릴-인다졸, 그의 제조방법 및 제초제로의 용도
KR970704715A (ko) 사카린 유도체(Saccharin Derivatives)
DE69815380D1 (de) N,n'-bis (sulfonyl) hydrazine die als antineoplastische mittel nützlich sind
ATE241594T1 (de) N-phenylacetoacetamide und verfahren zu ihrer herstellung
EA200500032A1 (ru) Производные ацилоксипирролидина и их применение в качестве лигандов v1b или v1b и v1a рецепторов
KR930019598A (ko) 인단-1,3-디온유도체 및 이들을 유효성분으로 함유한 제초제
KR920012100A (ko) 비스포스폰산 유도체, 이의 제조 및 용도
DE69928610D1 (de) Verfahren zur Herstellung von 2-Carbamoyl-Pyridinen
KR890002015A (ko) 2-니트로-5-(치환된 피리딜옥시)벤조히드록 심산 유도체
KR940014390A (ko) 3'-o-프로파르길-트리플루오로티미딘의 티오에스테르 유도체, 이의 제조방법 및 이를 유효 성분으로 하는 제암제

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties